09:00 - 10:24
Qol-O
PROCLIPI studies & Quality of Life | Oral presentations
Chair/s:
Julia Jane Scarisbrick, Richard Andrew Cowan, Emilio Berti
09:00 - 09:12
Qol-O-01
Experience of a supra-regional cutaneous lymphoma centre during the COVID-19 pandemic
Oral presentation
Uyen Nguyen
(Department of Dermatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom)
 
09:12 - 09:24
Qol-O-02
Time-to-Next-Treatment and Time-to-Next-Systemic Treatment in patients included in the PROCLIPI registry
Oral presentation
Pietro Quaglino
(Dermatologic Clinic, University of Turin Medical School, Torino, Italy)
 
09:24 - 09:36
Qol-O-03
Prognostic Factors in Mycosis Fungoides & Sézary Syndrome: Results from the PROCLIPI Study
Oral presentation
Julia J Scarisbrick
(University Hospital Birmingham, Birmingham, United Kingdom)
 
09:36 - 09:48
Qol-O-04
EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with Mycosis Fungoides and Sézary Syndrome: A real world data in Spanish patients (MICADOS Study)
Oral presentation
María del Mar Onteniente Gomis
(Hospital Universitario 12 de Octubre, Dermatology Department, Madrid, Spain)
09:48 - 10:00
Qol-O-05
An Update on Health-Related Quality of Life from the PROCLIPI Study
Oral presentation
Kevin Molloy
(University Hospitals Birmingham, Birmingham, United Kingdom), et al.
 
10:00 - 10:12
Qol-O-06
Development of EORTC/CLTF questionnaire to assess HRQOL in primary cutaneous T-cell and B-cell lymphomas: Phase I
Oral presentation
Kevin Molloy
(University Hospitals Birmingham, Birmingham, United Kingdom)
 
10:12 - 10:24
Qol-O-07
The role of illness perception in patients with cutaneous t-cell lymphoma
Oral presentation
Austin Burns
(Department of Dermatology, Johns Hopkins University, Baltimore, MD, United States)